^
21h
Primary oculomotor nerve malignant peripheral nerve sheath tumor in an infant: reflex-mediated biopsy failure and tubular port-assisted diagnostic escalation. (PubMed, Childs Nerv Syst)
Primary MPNST of the oculomotor nerve represents an exceptionally rare and surgically challenging entity. In selected deep cranial nerve-related lesions complicated by reflex-mediated instability, tubular port-assisted biopsy with endoscopic guidance may constitute a safe and effective diagnostic escalation strategy.
Review • Journal
|
SOX10 (SRY-Box 10)
1d
Atypical Neurofibromatous Neoplasms of Uncertain Biological Potential in Children with Neurofibromatosis Type 1: Report of Two Patients and Review. (PubMed, Int J Surg Pathol)
Patient 1: a 13-year-old boy developed a lumbogluteal nodule despite prior selumetinib...When feasible, complete excision is preferred; unresectable lesions need closer imaging. Early recognition widens cure opportunities and may refine risk stratification.
Journal
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CD34 (CD34 molecule) • SOX10 (SRY-Box 10)
|
TP53 wild-type
|
Koselugo (selumetinib)
1d
Imaging features and the role of image-guided biopsy for assessment of premalignant versus malignant peripheral nerve sheath tumors in neurofibromatosis type 1. (PubMed, Neurooncol Pract)
The presence of intralesional necrosis, perilesional enhancement, and edema; higher T2 heterogeneity; large diameter (>10.5 cm) and average diameter (8.3 cm); and a lower ADCmin (<0.7 × 10-³ mm²/s) are associated with high-grade MPNST in people with NF1. As efforts continue to more precisely define transitional tumors molecularly, histologically, and clinically versus high-grade MPNST, these data contribute to the MRI diagnostic distinctions.
Journal
|
NF1 (Neurofibromin 1)
6d
SWOG S1609: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors (clinicaltrials.gov)
P2, N=818, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
Trial completion date • Trial primary completion date
|
CD4 (CD4 Molecule)
|
PD-L1 overexpression
|
Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
13d
Novel genomic risk stratification model for primary high-grade malignant peripheral nerve sheath tumor (MPNST). (PubMed, J Pathol)
Collectively, genomic alterations detected by clinical NGS panels provide potential new biomarkers for risk stratification that can be integrated with conventional parameters to provide improved prognostication and guide therapeutic strategies.
Journal
|
TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • TERT (Telomerase Reverse Transcriptase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
|
TP53 mutation • TP53 wild-type • CDKN2A deletion
|
MSK-IMPACT
15d
Combined Soft and Hard Tissue Facial Lesions In Early Childhood Pioneering the Diagnosis of the Tumor Predisposition Syndrome Neurofibromatosis Type 1. (PubMed, Cancer Diagn Progn)
In individual cases, dental findings can provide clues for estimating the timing of the interaction between PNF and hard tissues which can apparently date back to the prenatal phase. The skeletal findings can already be identified on plain radiographs of the skull.
Journal
|
NF1 (Neurofibromin 1)
15d
Immune landscape characterization of neurofibromas with atypical features in Neurofibromatosis1 reveals PD-1 and the Tim-3/Galectin-9 pathway as potential therapeutic targets. (PubMed, Acta Neuropathol Commun)
Additionally, loss of H3K27me3 was associated with even lower densities of CD3+ T-cells and CD163+ macrophages in MPNSTs, and the loss of p16 seemed to act synergistically. Taken together, these findings suggest that an immune response involving both T-lymphocytes and macrophages may play a role in controlling or delaying the malignant transformation of ANF/ANNUBPs into MPNSTs and point to IC molecules as novel immunopreventive strategies in NF1 patients with ANF/ANNUBPs.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2) • CD163 (CD163 Molecule) • CASP3 (Caspase 3) • LGALS9 (Galectin 9) • SUZ12 (SUZ12 Polycomb Repressive Complex 2 Subunit)
18d
Neurofibromatosis type 1 with bladder neurofibroma followed by retroperitoneal malignant peripheral nerve sheath tumor: a case report. (PubMed, Urol Case Rep)
Despite subtotal resection and pazopanib therapy, the disease progressed and the patient died at 14 years of age. This case highlights persistent functional morbidity and later malignant progression during the long-term course of NF1-associated pelvic disease.
Journal
|
NF1 (Neurofibromin 1)
|
pazopanib
19d
Trial completion date • Pan tumor
|
STK11 (Serine/threonine kinase 11) • NF1 (Neurofibromin 1) • KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
STK11 mutation • KEAP1 mutation • NFE2L2 mutation
|
telaglenastat (CB-839)
20d
STRIvE-02: B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults (clinicaltrials.gov)
P1, N=68, Active, not recruiting, Seattle Children's Hospital | Trial primary completion date: Dec 2025 --> Dec 2040
Trial primary completion date
|
Keytruda (pembrolizumab) • SCRI-CARB7H3(s) • SCRI-CARB7H3(s)x19
25d
Case Report: Partial neurectomy and limb-sparing treatment for SOX-10 expressing epithelioid malignant nerve sheath tumour of the tibial nerve. (PubMed, Front Vet Sci)
The dog improved rapidly, and at 12- and 24-month follow-ups showed no recurrence or metastasis. This case demonstrates an atypical anatomical and histopathological presentation of canine EMPNST and shows that complete limb-sparing partial neurectomy can achieve long-term remission without compromising limb function.
Journal
|
SOX10 (SRY-Box 10)
25d
A case report of malignant transformation in neurofibromatosis type 1: pain and rapid growth as key indicators for early biopsy. (PubMed, Front Oncol)
No adjuvant targeted therapy was administered, and no recurrence was observed during the six-month follow-up. This case highlights the coexistence of NF1 and MPNST, aiming to enhance clinical awareness of the malignant transformation risks in NF1, thereby promoting earlier diagnosis and minimizing the potential for misdiagnosis and delayed intervention.
Journal
|
NF1 (Neurofibromin 1)